AmeriServ Wealth Advisors’s AbbVie ABBV Stock Holding History

AmeriServ Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-928	Closed	-$202K	–	55
2026 Q1	$202K	Sell	928 -115	-11%	-$25.5K	0.13%	58
2025 Q4	$238K	Buy	+1,043	New	+$238K	0.14%	55
2025 Q1	–	Sell	-1,882	Closed	-$334K	–	62
2024 Q4	$334K	Buy	+1,882	New	+$346K	0.18%	49
2023 Q2	–	Sell	-1,700	Closed	-$271K	–	44
2023 Q1	$271K	Sell	1,700 -75	-4%	-$11.5K	0.62%	36
2022 Q4	$287K	Hold	1,775	–	–	0.57%	36
2022 Q3	$238K	Sell	1,775 -200	-10%	-$28.7K	0.52%	40
2022 Q2	$302K	Sell	1,975 -56	-3%	-$8.56K	0.71%	38
2022 Q1	$329K	Hold	2,031	–	–	0.24%	52
2021 Q4	$275K	Hold	2,031	–	–	0.19%	53
2021 Q3	$219K	Sell	2,031 -125	-6%	-$14.3K	0.17%	62
2021 Q2	$243K	Sell	2,156 -60	-3%	-$6.76K	0.19%	61
2021 Q1	$240K	Buy	2,216 +11	+0.5%	+$1.18K	0.21%	57
2020 Q4	$236K	Buy	+2,205	New	+$212K	0.23%	61
2014 Q2	–	Sell	-4,300	Closed	-$221K	–	117
2014 Q1	$221K	Sell	4,300 -9,650	-69%	-$488K	0.22%	119
2013 Q4	$737K	Buy	13,950 +400	+3%	+$19.7K	0.44%	69
2013 Q3	$606K	Buy	13,550 +100	+0.7%	+$4.43K	0.39%	77
2013 Q2	$556K	Buy	+13,450	New	+$588K	0.36%	80

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AmeriServ Wealth Advisors's ABBV Position: Q2 2026 in Review

AmeriServ Wealth Advisors sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 928 shares — an estimated $202K sold.

AmeriServ Wealth Advisors first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $737K in Q4 2013. 4,218 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

AmeriServ Wealth Advisors reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
AmeriServ Wealth Advisors sold 928 AbbVie shares in Q2 2026, an estimated $202K.
AmeriServ Wealth Advisors first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
AmeriServ Wealth Advisors's AbbVie position peaked at $737K in Q4 2013.
4,218 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AmeriServ Wealth Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.